BioPharma « Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 3

703 Posts, Pagina: « 1 2 3 4 5 6 ... 27 28 29 30 31 32 33 34 35 36 » | Laatste

Omlaag ↓

[verwijderd] 2 januari 2011 22:50

Ik zit hier ook al weer enige jaren in. Ik doe ze niet weg, zeker niet voor de paar dubbeltjes die ze nu waard zijn. De kans dat dit ooit nog een keer goed komt is zeker aanwezig. We kijken het nog wel weer een jaar aan.

Groet,
Chico

svenhedin 6 januari 2011 20:49

From Yahoo

big cancer news out of GNBT! $$

6-Jan-11 01:32 pm go Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
8:30a ET January 6, 2011 (PR NewsWire)
Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), and RXi Pharmaceuticals Corporation (www.rxipharma.com) (NasdaqCM: RXII), a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

Initial results from the collaboration demonstrated success in using RXi's proprietary self-delivering rxRNA(TM) (sd-rxRNA(TM)) compounds to silence genes up to 80% in hemopoietic cells. The ability to knock down expression of certain genes in isolated hemopoietic-derived cancer cells (ex vivo) has the potential to convert them into specific immune-stimulants and opens the possibility for development of a new class of anticancer therapeutic vaccines. RXi's sd-rxRNA compounds may be particularly suitable for this use, since they are able to cross cell membranes without the assistance of any delivery agent.

"We are very pleased to have identified a technology that enables efficient RNAi silencing in hemopoietic cells," said Dr. Eric von Hofe, President of Antigen Express. "These types of cells are notoriously difficult to deliver RNAi and other oligonucleotide molecules to. In contrast to other gene silencing technologies, RXi's compounds act more like small molecules, which may greatly facilitate clinical development."
(

[verwijderd] 28 januari 2011 07:02

Howdy,

Jan. 27/'11

After a period of relative silence from Generex (GNBT), aside from a late day 8k announcement on Friday, a couple of press releases issued on Tuesday show that the lights are on in Worcester. It was first announced that the company had agreed to monetary terms with "certain institutional investors" that would put at least three million dollars in the Generex coffers, but the deal could bring in up to six million, if the "certain" investors were to purchase the full allotment of shares and warrants offered.

Generex will use the proceeds to fund ongoing trials and - of course - for general corporate purchases, which covers just about everything from electric bills and salaries to business meeting at Scores.

Also on Tuesday it was announced that Generex will increase the amount of patients enrolled in the ongoing Phase II trial testing AE37 for breast cancer. According to the release, the increase in enrollment will ensure that all patient groups are well represented in this trial before consideration shifts to the planned Phase III trial.

If this move validates the Phase II trial any more than it would have been anyway, then good on Antigen Express - the Generex subsidiary who is bringing AE37 through development - but it's a little premature to be looking toward Phase III. Let's make sure Phase II turns out as planned, which the boost in enrollment may be a move to do just that.

That said, the fact that the enrollment boost is coming mid trial will have some speculating as to why the move was needed now and not planned in originally. Generex offered another nugget in that AE37 release on Tuesday by announcing that an independent valuation firm, one that specializes in pharmaceuticals, had put a $300 million value on AE37 at its current stage in development. Not surprisingly, the company thought that this value was conservative, although investors may disagree as the current market cap for GNBT is still under 75 million.

It's tough to place too high a value on a Phase II company, in my opinion (never was a fan of GERN when it was trading with a market cap of closer to a billion than to half a billion), no matter how promising a product candidate may be, but I'll buy the fact that this stock should be trading significantly higher if anyone were taking Oral-lyn and/or AE37 seriously.

It's still my opinion that Generex is looking to sell or partner AE37, hence the "independent" valuation thrown out there, but investors are more intent on hearing news regarding Oral-lyn. THAT is the flagship product and the short term catalyst for which investors are awaiting an update.

All this talk about AE37 over the past few months - while nothing has been mentioned about Oral-lyn - will no doubt have investors believing that the company is leading them toward the bright, shiny object and away from where the attention should be.

This company can have quite the flair for the dramatic when need be, even when things get a little ridiculous, but it's all ho-hum right now until we get an Oral-lyn update.

For twenty six cents***, however, couldn't resist picking up a few shares because if Oral-lyn does kick back solid results, then GNBT will be trading much, much higher in no time.

bron:

seekingalpha.com/article/249193-gener...

Houdoe,

>--:-)-->

p.s.***Koers eindigde op 25 cent.

gustaaf1e 30 januari 2011 21:32

Samenvatting van een artikel over Oral-lyn in "Diabetes, Obesity and Metabolism", a journal of Pharmacology and therapeutics.
Zeer positieve conclusie.

Keywords:buccal spray insulin;diabetes;IGT;insulin therapy
Aim: Postprandial hyperglycaemia is a consequence of reduced first phase insulin response and is associated with increased cardiovascular risk and mortality. The aim of this proof-of-concept study was to investigate the safety and efficacy of treatment with buccal spray insulin (Oral-lyn™, Generex Biotechnology Corporation, Toronto, Ontario, Canada) on postprandial plasma glucose and insulin levels in subjects with impaired glucose tolerance (IGT).

Methods: A total of 19 female and 12 male Caucasian subjects, 52.2 ± 13.5 (SD) years old, having a body mass index of 33.1 ± 6 (SD) kg/m2 with confirmed IGT were included in the study. Subjects were randomized to take 4, 6 or 12 Oral-lyn puffs (1 puff = 1 s.c. rapid insulin UI) split into two equal doses each, one before and the second 30 min after a standard 75 g oral glucose tolerance test (OGTT). Glucose and insulin levels were measured at baseline and 30, 60, 90, 120 and 180 min afterwards.

Results: Glucose fluctuations during OGTT were not modified by 4 or 6 Oral-lyn puffs. Treatment with 12 puffs was followed by 29.6% decrease in plasma glucose at 2 h and 26.8% decrease at 3 h, altogether p = 0.01. Considering all time points of the OGTT, there was a mean reduction of 15.8% in glucose levels. With 6 of the total 12 puffs used in group C there was a significant increase in the insulin levels during OGTT at 30 min (p < 0.04) but not at 2 or 3 h. No hypoglycaemic episodes were observed at any time points of the OGTT.

Conclusions: This proof-of-concept study demonstrates that treatment with buccal spray insulin is a simple and valuable therapy for reducing postprandial hyperglycaemia in obese subjects with IGT. Importantly, this treatment is safe and none of the study subjects experienced hypoglycaemia.

NB: Waarom haalde Generex onlangs zo'n luttel bedrag van $3 miljoen op? Worden er op korte termijn andere inkomsten verwacht? Want met zo'n relatief klein bedrag kunnen ze net enkele maanden vooruit...
G

svenhedin 31 januari 2011 13:46

Eindelijk eens bericht met hoopvol nieuws (bovenstaand) over Oral-Lyn.
Aanbevolen wat mij betreft.
De koers is om te huilen op dit moment.

[verwijderd] 1 februari 2011 21:04

Tjonge jonge,... waar gaat dit heen? Is dit aandeel niet meer waard dan 2 duppies? Ik word er moedeloos van.....

svenhedin 2 februari 2011 22:22

quote:
Peermanpaapskop schreef op 1 februari 2011 21:04:
Tjonge jonge,... waar gaat dit heen? Is dit aandeel niet meer waard dan 2 duppies? Ik word er moedeloos van.....

Uhhhhh...€ 0,17 ongeveer

gustaaf1e 2 februari 2011 22:29

Sven,
Toch minimaal een $kwartje, gezien die $3.000.000 voor 12.000.000 stukjes.
G

svenhedin 3 februari 2011 13:34

quote:
gustaaf1e schreef op 2 februari 2011 22:29:
Sven,
Toch minimaal een $kwartje, gezien die $3.000.000 voor 12.000.000 stukjes.
G

OK, € 0,18 dan.

gustaaf1e 3 februari 2011 20:14

Is ook goed,
G

svenhedin 14 februari 2011 20:03

Opfrissertje (voor de volhouders):

Generex Technology

Generex have many platform technologies in the area of drug delivery and immunomedicines.

Drug Delivery - RapidMist™:

Comprised of a proprietary device & pharmaceutical agents in an aerosolized liquid formulation.

Delivered through the buccal mucosa (inner cheek of mouth) and NOT THE LUNGS.

Applicable to most proteins and peptides.

Antigen Express technology focuses on modulating immune responses mediated by T helper (Th) cells, a class of lymphocytes that plays a multifaceted role in the immune system, both enhancing and suppressing immune responses. The cells are essential both for obtaining a robust and long lasting response against infectious agents or cancer cells and for down regulating immune responses when the immune system becomes inappropriately stimulated, e.g. in autoimmune disease and allergy.

Product Pipeline

www.generex.com/technology.php

svenhedin 14 februari 2011 20:09

Is dit bericht al bekend ?

Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
Feb 3, 2011 9:00:00 AM

Close Ad
Email story | Discuss on ZenoBank | View more ads WORCESTER, Mass., Feb. 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine. The Company has previously received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform. The current allowance strengthens independent composition of matter claims directed to the AE37 peptide. The full term of the new patent will extend through January 5, 2028.

(Logo: photos.prnewswire.com/prnh/20110106/N... )

AE37 is currently the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. Favorable results from this study have been reported previously. This immunotherapeutic vaccine also has been tested in a Phase I study in patients with prostate cancer, which confirmed the safety and immunogenicity observed in the prior breast cancer study. In addition to breast and prostate cancer, many other types of cancer, such as lung, colon, stomach and bladder, also express the HER2 protein, which is the target for an AE37 stimulated immune response.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation

----------------------------------------------
Todd Falls
Investor Relations Contact
Generex
800-391-6755
or Howard Gostfrand
Investor Relations Contact
American Capital Ventures
Inc.
877-918-0774
or Christina Markowitch
Media Contact
Beckerman Public Relations

gustaaf1e 14 februari 2011 21:24

Ja Sven,
Dat bericht was bekend.
En verder: nog ff w88, hh:)
En nog ff w88....
Zou het nog ooit wat worden met dit bedrijf/aandeel?

G

svenhedin 4 maart 2011 19:10

quote:
gustaaf1e schreef op 14 februari 2011 21:24:
Ja Sven,
Dat bericht was bekend.
En verder: nog ff w88, hh:)
En nog ff w88....
Zou het nog ooit wat worden met dit bedrijf/aandeel?

G

HOOP doet LEVEN !

[verwijderd] 23 maart 2011 08:17

GNBT

gisteren een nieuwtje

money.msn.com/business-news/article.a...

svenhedin 25 maart 2011 17:17

Kruipt o
Kruipt omhoog richting 31 maart.
$0,28 nu.

gustaaf1e 25 maart 2011 17:33

quote:
svenhedin schreef op 25 maart 2011 17:17:
Kruipt o
Kruipt omhoog richting 31 maart.
$0,28 nu.

Sven,
kleine correctie op je bericht:
Press conference niet 31 maart, maar 30 maart, 1:00 pm ET.
+ 12,5% nu.
G

svenhedin 25 maart 2011 17:34

quote:
svenhedin schreef op 25 maart 2011 17:17:
Kruipt omhoog richting 31 maart.
$0,28 nu.

Herstel: 30 maart

gustaaf1e 30 maart 2011 19:48

Pff, press conference gezien. Weinig uitstraling. Saai, uit het hoofd geleerde verhaaltje. Leek wel of ze alle 5 erg zenuwachtig waren.
Krijg spontaan heimwee naar Anna....

G

gustaaf1e 30 maart 2011 19:52

Wel aardig koopmoment trouwens.
G

703 Posts, Pagina: « 1 2 3 4 5 6 ... 27 28 29 30 31 32 33 34 35 36 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 913,25 -0,31 -0,03% 17 mei


Germany40^	18.716,50	-0,12%
BEL 20	4.004,80	+0,24%
Europe50^	5.069,27	+0,10%
US30^	39.995,10	0,00%
Nasd100^	18.540,20	0,00%
US500^	5.302,48	0,00%
Japan225^	38.732,00	0,00%
Gold spot	2.415,21	0,00%
EUR/USD	1,0874	+0,04%
WTI	79,51	0,00%